GSK plc (GSK): what the price assumes

boothcheck covers GSK plc (GSK) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-07-26.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/GSK

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7.4% cost of capital with 4% terminal growth over a 5-year stage.

Reconcile: at the x-ray's 9.3% required return this reads ~2%/yr; the models below use their own rates.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.8%); the inversion above states its own rate.

Per-Model Detail (n=18)

Solvency

Bullet Takeaways

• Specialty Medicines has become the engine of the group, with 2025 sales of 13.5 billion pounds up 17% at constant currency, oncology inside it up 43% and HIV at 7.7 billion pounds.
• The patent schedule in the 2025 annual report puts Trelegy Ellipta, the largest product in the General Medicines business, at first expiry in 2027, and General Medicines sales already fell 6% in the first quarter of 2026.
• Second-quarter results arrive on 28 July 2026, the first print to carry Jideytro, approved in the US on 22 July for previously treated ROS1-positive lung cancer.

Bull Case

Follow the money GSK spent in 2025 and the strategy stops being a slogan. The company put 7.5 billion pounds into research, ran a 2 billion pound buyback of which 1.7 billion had been executed by the first quarter of 2026, declared a 17p first-quarter dividend against 70p expected for the full year, and then in June 2026 agreed to buy Nuvalent for 10.6 billion dollars. Research got the largest share by a wide margin. That is a management team saying, with money rather than slides, that the next decade of this business gets bought in laboratories rather than returned to holders.

The 20-F is blunt about the scale of it. GSK states "In 2025, total R&D expense was £7.5 billion, up 18% AER, 19% CER. We have 58 assets in our pipeline with over half of these coming through business development." The second half of that sentence is the more interesting one. GSK is not primarily inventing its pipeline; it is buying and partnering its way to one, and it says so plainly: "Over half of our pipeline has been shaped through business development and strategic partnerships with leading academic institutions and pioneering companies at the forefront of scientific and technological innovation." For a company whose internal discovery record has been picked over for two decades, outsourcing the origination step while keeping the development and commercial machine is a reasonable trade.

It is working where it has been aimed. Specialty Medicines reached 13.5 billion pounds of sales in 2025, up 17% at constant currency, with respiratory, immunology and inflammation at 3.8 billion pounds up 18%, oncology at 2.0 billion pounds up 43%, and HIV at 7.7 billion pounds up 11%, Dovato alone contributing 2.7 billion pounds and growing 22% [FY2025 20-F]. Specialty is now the largest of the three businesses. It was not the largest a few years ago. That shift is the whole reinvention, visible in a single line of the segment note.

The Nuvalent purchase converted into a product faster than anyone scheduled. GSK closed the acquisition on 15 July 2026 and the FDA approved Jideytro, the ROS1 inhibitor zidesamtinib, on 22 July, ahead of its original 18 September target action date. It is the company's first approval in lung cancer. A second asset from the same deal, neladalkib, carries an FDA decision date of 27 November 2026. Buying a clinical-stage company and holding a marketed drug seven days later is unusual, and it means the June commitment is already partly de-risked in a way the announcement itself could not assume.

None of this requires heroic arithmetic to matter. Group turnover reached 32,667 million pounds in 2025, up 7% at constant currency, and reported operating profit came in at 7,932 million pounds against 4,021 million a year earlier [FY2025 20-F]. Set the top-line pace beside the large US majors: MRK grew revenue about 2.9% and PFE about 1.4% over their own trailing years. GSK is not the fastest-growing name in the cohort, but it is growing faster than the two US companies most often used to define what a mature pharmaceutical business looks like, and it is doing so while funding the largest research budget in its own history.

Bear Case

Start with what the balance sheet actually holds. At the end of 2025 GSK carried 3,397 million pounds of cash and 9 million pounds of liquid investments against 3,012 million pounds of short-term borrowings and 14,708 million pounds of long-term borrowings [FY2025 20-F]. Then, in July 2026, it paid 10.6 billion dollars for Nuvalent. The year-end accounts do not contain that outlay. Neither do they contain the dividend commitment of 70p a share for 2026, nor the remainder of the 2 billion pound buyback. Trading profit covers the interest bill many times over, so this is not a solvency question. It is a flexibility question, and flexibility is what a company facing an expiry schedule needs most.

The expiry schedule is the second problem. The 20-F's own patent table lists Seretide and Advair as expired, Flixotide and Flovent as expired, and Trelegy Ellipta, the largest remaining product in General Medicines, with first expiry falling in 2027. General Medicines sales declined 1% at constant currency across 2025 and then fell 6% in the first quarter of 2026. Vaccines, the other third of the group, was stable in 2025 and grew 4% in the first quarter of 2026, but Arexvy fell 18% in that quarter. Two of the three businesses are flat or shrinking. Specialty has to carry all of them.

The reported profit trajectory flatters what happened underneath. Operating profit nearly doubled in 2025, from 4,021 million pounds to 7,932 million pounds, an increase of about 3.9 billion. The same note reports transaction-related items of 507 million pounds in 2025 against 1,881 million in 2024, and significant legal, divestments and other items swinging from a 1,577 million pound loss in 2024 to a 453 million pound gain in 2025 [FY2025 20-F]. Those two lines alone account for roughly 3.4 billion pounds of the improvement. The trading business got better in 2025. It did not get twice as good.

Pipeline risk here is not a theoretical category on a risk register. On 17 July 2026 GSK reported that camlipixant met its primary endpoint in the CALM-1 phase III trial but missed it in CALM-2, that key secondary endpoints missed in both, and that "the limited efficacy demonstrated is unlikely to transform patient care", and it discontinued development in refractory chronic cough. Twelve weeks earlier the company had listed camlipixant first among four pivotal 2026 readouts. That is how quickly a named future revenue line becomes a press release.

All of which connects to what the market is paying for. The earnings-power methods, the ones that capitalise today's profit and credit nothing new arriving, sit well under the quote, roughly 51% under it. The distance between that earnings-power family and the market is, quite literally, the pipeline. If Specialty decelerates while General Medicines runs off, the buyer is left holding the methods that assume nothing new, not the ones that assume a decade of successful replacement. The 20-F's commercial-practices risk describes intensifying pricing and access pressure across major markets, with US trade and drug-pricing policy singled out as the dominant uncertainty of 2025, and that pressure lands hardest on exactly the mature portfolio that is already declining.

Valuation

The unusual thing about GSK's quote is how little it demands. Run the price backwards and it does not embed a growth story at all. It sits below what even a 5% a year decline in operating profit would warrant, which means a buyer is not underwriting the pipeline working. They are underwriting the business not shrinking faster than mid single digits. That is a materially different bet from the one most pharmaceutical prices carry, and it is worth sitting with before looking at any method.

Put the same thing in margin terms. Today's quote is consistent with company-wide operating margins settling near 7.2% and staying there. In 2025 the group earned 7,932 million pounds of reported operating profit on 32,667 million pounds of turnover [FY2025 20-F], and the first quarter of 2026 ran at a 30.1% total operating margin on turnover of 7,629 million pounds. The market is priced for roughly a third of what the business currently converts. Getting there would take an expiry cycle far more destructive than the one the patent table describes.

The methods split cleanly, and the split is informative rather than confusing. Peer-multiple approaches and the cash-flow approaches both land above the current quote. The methods that capitalise trailing profit with no growth land below it, roughly 51% under, and book-value-plus-profitability approaches land below too, about 21% under that asset family. Read it as one sentence: measured against what comparable companies fetch, GSK looks inexpensive; measured against what it earns today with nothing new ever arriving, it does not. Both readings are true, and the space between them is the replacement question.

The cohort comparison sharpens it. GSK grew turnover 7% at constant currency in 2025 while MRK grew revenue about 2.9%, PFE about 1.4%, and BMY about 1.8% over their own trailing years. The large-cap pharmaceutical group is mostly not growing. A company inside that group that is growing, and whose growth is concentrated in the segment with the longest remaining exclusivity, is not obviously the one that should carry the lowest multiple of the set.

Balance-sheet resilience is real but it is not slack. Borrowings of 17.7 billion pounds against 3.4 billion pounds of cash and liquid investments at the end of 2025 leave leverage under two years of trading profit, and the company generated 1,350 million pounds from operations in the first quarter of 2026. Share count has been essentially flat since 2021, growing 0.3% a year, so the 2 billion pound buyback has offset issuance rather than shrunk the base. Holders are being paid in dividends, not in a falling share count, and the 10.6 billion dollars that left in July went into the pipeline instead.

Catalysts

The nearest event is three days out. GSK confirmed on 22 May 2026 that second-quarter results will be published on 28 July 2026. It is the first print since the company reaffirmed full-year 2026 guidance of 3% to 5% turnover growth at constant currency alongside its first-quarter numbers, and the first to sit on the far side of two events that changed the shape of the year.

The first was the Nuvalent acquisition, agreed on 9 June 2026 for 10.6 billion dollars and completed on 15 July. Seven days after closing, the FDA approved Jideytro for previously treated ROS1-positive non-small cell lung cancer, ahead of its 18 September target action date, giving GSK its first marketed lung cancer product. The second Nuvalent asset, neladalkib, has an FDA decision date of 27 November 2026, which makes the fourth quarter the next binary event on the calendar. Elsewhere in the portfolio, the FDA approved the oral antibiotic tebipenem for complicated urinary tract infections on 17 June 2026, and the EMA accepted a filing for a single-dose Bexsero booster on 20 July.

The second event ran the other way. On 17 July 2026 GSK discontinued camlipixant in refractory chronic cough after the CALM-2 phase III trial missed its primary endpoint. That removes one of the four pivotal 2026 readouts the company had flagged in April. The three that remain are Jemperli in rectal cancer, where positive data were reported on 13 July 2026, a three-times-yearly HIV pre-exposure prophylaxis regimen, and Exdensur in EGPA. Guidance for 2026 and the 2031 outlook of more than 40 billion pounds of sales were both reaffirmed in April; whether they survive the July results is the question the print answers.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• NVS (Novartis AG)
• FY2025 20-F: …behind priority brands and launches. Core operating income margin from continuing operations was 40.1% of net sales, increasing 1.4 percentage points (2.1 percentage points cc). Core net income was USD 17.4 billion (+11%, +12% cc), mainly due to higher core operating income. Core basic earnings per share was USD 8.98…
• FY2025 20-F: …biosimilar competitor products are approved, including the strength of the market for generic or biosimilar pharmaceutical products in such geographies, and the comparative profitability of branded pharmaceutical products in such geographies; and our ability to successfully develop and launch new products for…
• AZN (ASTRAZENECA PLC)
• FY2025 20-F: …that there is not the clear link that exists in many manufacturing businesses between the revenue generated on an individual product sale and the associated cost and hence margin generated on a product. Consequently, the profitability of individual drugs or classes of drugs is not considered a key measure of…
• FY2025 20-F: …conditions could adversely affect supply and/or distribution in affected countries and the ability or willingness of customers to purchase our medicines, putting pressure on price and/or volumes. This could adversely affect our business or results of operations, for example, those healthcare systems most severely…
• MRK (Merck & Co., Inc.)
• FY2025 10-K: …include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, generic drug manufacturers, and animal health care companies. The Company's operations may be adversely affected by generic and biosimilar competition as the Company's products mature, as…
• FY2025 10-K: …and the Health Care Environment," global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare,…
• PFE (Pfizer Inc.)
• FY2025 10-K: …to patents covering products for which we have patent rights, licenses or co-promotion rights. See Note 16A1 . We may become subject to competition from biosimilars referencing our biologic products if competitors are able to obtain marketing approval for such biosimilars. We also commercialize biosimilar products…
• FY2025 10-K: …us for the development of technologies and processes or greater experience in particular therapeutic areas, and technological innovation and/or consolidation among certain pharmaceutical and biotechnology companies can enhance such advantages. These advantages may make it difficult for us to compete with them…
• BMY (Bristol-Myers Squibb Company)
• FY2025 10-K: …consolidation and integration of pharmacy chains, wholesalers and pharmacy benefit managers will increase competitive and pricing pressures on pharmaceutical manufacturers, including us. Third-party royalties represent a significant percentage of our pretax income and operating cash flow. We have entered into several…
• FY2025 10-K: …in more efficient operations and putting us at a competitive disadvantage. These risks may result in an adverse impact on our business, financial condition or results of operations. 31 Strategic, Business Development and Employee Attraction and Retention Risks We depend on several key products for most of our…
• JNJ (Johnson & Johnson)
• FY2025 10-K: 2025, representing an increase of 10.1% as compared to the prior year. Growth of SPRAVATO (esketamine) was driven by continued increased physician and patient demand. Growth was partially offset by the sales decline of INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA primarily due to the impact of Medicare Part D…
• FY2025 10-K: …product advantages, pricing and availability and rate of reimbursement. The Company also competes with other market participants in securing rights to acquisitions, collaborations and licensing agreements with third parties. Competition for rights to product candidates and technologies may result in significant…
• ABBV (AbbVie Inc.)
• FY2025 10-K: …future periods. The CODM regularly reviews net revenues, net earnings and significant segment expenses and uses net earnings as its principal measure of segment profit or loss. Net earnings and significant segment expenses reviewed by CODM are reported on the consolidated statement of earnings for the years ended…
• FY2025 10-K: …from lower priced generic or biosimilar products. The expiration or loss of patent protection for a product typically is followed promptly by substitutes that may significantly reduce sales for that product in a short amount of time. If AbbVie's competitive position is compromised because of generics, biosimilars or…
• LLY (ELI LILLY & Co)
• FY2025 10-K: U.S. continue to significantly impact the market for pharmaceuticals through negotiation of access, manufacturer price or rebate concessions and pharmacy reimbursement rates. Restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory…
• FY2025 10-K: …with other pharmaceutical companies. For additional information, see Item 8, "Financial Statements and Supplementary Data-Note 3: Collaborations and Other Arrangements." Competition Our products compete globally with many other pharmaceutical products in highly competitive markets. Important competitive factors…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.